ALDX - Aldeyra Therapeutics, Inc.

1.57
-0.010   -0.637%

Share volume: 724,956
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$1.58
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 26%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.29%
1 Month
-6.55%
3 Months
-70.49%
6 Months
-68.94%
1 Year
-41.64%
2 Year
-61.23%
Key data
Stock price
$1.57
P/E Ratio 
N/A
DAY RANGE
$1.56 - $1.62
EPS 
-$0.56
52 WEEK RANGE
$1.07 - $6.18
52 WEEK CHANGE
-$40.75
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
60.183 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
0.10
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,222,776
AVERAGE 30 VOLUME 
$1,758,770
Company detail
CEO: Todd C. Brady
Region: US
Website: aldeyra.com
Employees: 10
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.

Recent news